CAR-T

#AAV #Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #RNA

This week in drug discovery (23-27 January)

News round-up for 23-27 January by DDW Digital Content Editor Diana Spencer. Cell and gene therapies have been making the news this week, as we launch our very own guide to global… Read More

#News

CAR-T therapy
#Cancer research #CAR-T #CARsgen Therapeutics #China #Collaboration #Huadong Medicine #Immunotherapy #Myeloma #Oncology #Partnership

Partners to commercialise CAR-T product in China

CARsgen Therapeutics and Huadong Medicine (Hangzhou) will collaborate on the commercialisation of CARsgen's BCMA CAR-T product CT053 in mainland China.  CT053 (zevorcabtagene autoleucel, Zevor-cel) is CARsgen's lead drug candidate and an autologous CAR T cell product treating relapsed/refractory multiple myeloma (R/R MM).  Dr Zonghai Li, Chairman of the Board, Chief… Read More

#Business & Investment #News

CAR-T cells attack cancer cells
#Cancer research #CAR-T #Cell and gene therapy #Cell therapy #High throughput screening #Immunotherapy #T cell activation

Watch now: Improve cell therapies with high-throughput CAR libraries

CAR-T cell therapies are a promising approach for treating solid tumours. But identifying appropriate T-cell receptor (TCR) domains that exclusively target tumour antigens remains a challenge. Toxicity, tumour activation, and tumour persistence are significant challenges to using CAR-T cell therapies for solid tumours. In this new on-demand… Read More

Webinar date:
Brought to you by Twist Bioscience
#Editor's Choice #News

CAR-T cells attack cancer cells
#Cancer research #CAR-T #Cell and gene therapy #Cell therapy #High throughput screening #Immunotherapy #T cell activation

Improving cell therapies with high-throughput CAR libraries

CAR-T cell therapies are a promising approach for treating solid tumours. But identifying appropriate T-cell receptor (TCR) domains that exclusively target tumour antigens remains a challenge. Toxicity, tumour activation, and tumour persistence are significant challenges to using CAR-T cell therapies for solid tumours. In this webinar, Twist Bioscience’s CSO, Aaron… Read More

Webinar date:
Brought to you by Twist Bioscience
#Webinars

#Biologics / Biotechnology #CAR-T #China #CRISPR #Drug discovery #Gene editing #Genetics / genomics #HIV #HPV #Oncology #Pharmacology #T cell activation #The Dose

The Dose: DDW’s drug discovery highlights

DDW highlights the most interesting global news and comments within the drug discovery and development sector this month.   Everyone enjoys a good news story and the drug discovery and development sector is no exception. Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening… Read More

#Exclusive Content

CAR-T therapy
#Autoimmune disease #Cancer #CAR-T #Immunotherapy #Mouse models

CAR-T therapy successfully used to treat autoimmune disease

CAR-T therapy can be used to eliminate unwanted cells that cause autoimmunity, according to the results of a new study in mice with an autoimmune disease similar to multiple sclerosis (MS).  CAR-T, which uses genetically altered immune cells to destroy cancer cells, has revolutionised treatment of some… Read More

#News #Trending News

#CAR-T #Drug discovery #eBook #Immuno-oncology

Latest eBook: Innovation in immuno-oncology

This 28-page eBook sponsored by Twist Bioscience features insights and expert opinions on the latest advancements occurring in immuno-oncology and drug discovery. Read this eBook to learn about: The challenges and opportunities facing CAR-T cell therapies Targeting GPCRs in cancer drug discovery The immuno-oncology landscape and its many pathways Access… Read More

#News

#CAR-T #Drug development #Immuno-oncology

Advancements driving drug discovery in immuno-oncology

This latest 28 page eBook sponsored by Twist Bioscience features insights and expert opinions on the latest advancements occurring in immuno-oncology and drug discovery. Read this eBook to learn about: The challenges and opportunities facing CAR-T cell therapies Targeting GPCRs in cancer drug discovery The immuno-oncology landscape and its many… Read More

#DDW eBooks #Intelligence

#Advanced Therapies Europe #CAR-T #Cell and gene therapy #Cell therapy #Collaboration

On the European CGT landscape, zebras and the future of medicine

Listen to this article on the DDW podcast: Alongside industry professionals interested in the cell and gene therapy landscape in Europe, DDW’s Multimedia Editor Megan Thomas was welcomed to Advanced Therapies Europe 2022 by Phacilitate’s Vice President, Becky Johnson-Kent. Johnson-Kent introduced the notion of the zebra company and compared its two-fold… Read More

#Editor's Choice #Exclusive Content

#CAR-T #European Commission #Oncology

European Commission approves Yescarta  

The European Commission (EC) has approved biotechnology company Kite’s CAR T-cell therapy Yescarta for patients with follicular lymphoma (FL).  Specifically the approval is for adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.  The approval was based… Read More

#News

#Antibiotics #CAR-T #Digital twin

This week in drug discovery (6-10 June) 

News round-up by DDW’s Reece Armstrong for 6-10 June Antibiotic developments, vaccines for MMR and business expansions are some of the features of this week’s news round-up. US gets another MMR vaccine option in GSK’s Priorix   GSK’s vaccine for the prevention of measles, mumps and rubella (MMR) has been… Read More

#News

#Biopharma #CAR-T #Cell therapy

Kite releases long-term data for cell therapy  

Biopharmaceutical company Kite has announced long-term follow up results of two studies for its CAR T-cell therapy Tecartus (brexucabtagene autoleucel). The results of both a three- and two-year follow-up of the company’s ZUMA trial were announced at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. … Read More

#News

#Cancer #CAR-T #Cell therapy

Cancer therapy guide available to download

This guide examines how cell and gene therapy transform cancer treatment. While cell therapies like CAR-T are promising cancer treatments, many challenges remain, including improving responses in blood cancers and efficacy in solid tumours. This new cancer therapy guide from 10x Genomics will outline: Cutting-edge single cell and spatial analysis technologies… Read More

#News

RNA
#CAR-T #Immunology / Virology & Vaccines #mRNA #T-Cells

Vaccine-like mRNA injection can be used to make CAR-T cells 

A study from researchers in the Perelman School of Medicine at the University of Pennsylvania has shown that an experimental immunotherapy can temporarily reprogramme patients’ immune cells to attack a specific target via only a single injection of mRNA, similar to the mRNA-based Covid-19 vaccines.  Context  The researchers, whose… Read More

#News

#CAR-T #GlobalData #Immunotherapy

Analysts expect competition in CAR-T therapies in Japan 

Janssen Pharmaceutical has recently filed for B-cell maturation antigen (BCMA) CAR-T therapy Cilta-cel in Japan. Earlier in March 2021, Bristol-Myers Squibb (BMS) filed for the first BCMA CAR-T therapy idecabtagene vicleucel, in the country. Following approval by the Japanese regulatory authority, BMS will have the first-mover advantage. However, stiff competition is expected… Read More

#News #Trending News